Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
Hippuran I-131 is a radioactive diagnostic agent containing iodine-131 labeled sodium iodohippurate, used for renal imaging and kidney function assessment via nuclear medicine. It is administered by injection to visualize renal perfusion and excretory function. This legacy radiopharmaceutical enables clinicians to evaluate glomerular filtration rate and diagnose renal disease.
As a legacy diagnostic with approaching loss of exclusivity and minimal linked opportunities, this product faces significant headwind and likely operates with a small, specialized team focused on compliance and legacy revenue preservation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Hippuran I-131 presents minimal active career opportunity, with zero linked job openings and a contracting market presence. Career roles on this product focus primarily on regulatory maintenance, manufacturing efficiency, and legacy portfolio management rather than growth or innovation.
Worked on HIPPURAN I 131 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.